Δευτέρα 10 Ιανουαρίου 2022

New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10

xlomafota13 shared this article with you from Inoreader

Bull Cancer. 2022 Jan 5:S0007-4551(21)00575-0. doi: 10.1016/j.bulcan.2021.09.021. Online ahead of print.

NO ABSTRACT

PMID:34998526 | DOI:10.1016/j.bulcan.2021.09.021

View on the web

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου